Vital signs will be assessed prior to and post infusion then every 15 minutes for 1 hour. TTRNA -DCs Intradermal 1x107 cells Days 1, 15, 29 Each immunization will be divided equally to both inguinal regions. A total volume of 200 µL per side will be delivered intradermally after preparation of skin with EMLA anesthetic cream. Sargramostim (GM -CSF) Intradermal 150 ug 1, 15 , 29 Embedded with DC Vaccine Filgrastim (G-CSF) SQ or IV 5 micrograms/ kg/day Beginning no later than Day 6 post- transplant - count recovery Per institutional guidelines Three days after completion of the myeloablative therapy (Day 0) , patients will be given their autologous PBSC transplant. Immunotherapy will commence 24 hours after autologous PBSC transplant with infusion of TTRNA -xALT via an intravenous catheter . The equally -divided TTRNA -DC vaccine embedded with GM -CSF will be injected intradermally into the groin bilaterally which drain to the inguinal lymph nodes (upper medial thigh). Peripheral blood will be drawn prior to non- mobilized leukapheresis , prior to immunotherapy , 1 day post Vaccine #1 , 4 (+/- 1) days post Vacci ne #1, weekly post Vaccine #1 for six weeks , and bimonthly , if feasible, until progression for T cell kinetics. Blood will be processed in accordance with SOP -UFBTIP -126. The subsequent DC vaccines #2 and #3 will occur at 2 week intervals following the first vaccine. Patients will receive Re-MATC H Protocol Page 45 of 106 Version: 20180628 at least 3 biweekly vaccines as long as clinically stable. Patients will receive G -CSF at 5 microgram /kg/day beginning no later than day 6 post -transplant until ANC recovers to >1000 cells/ µL. NOTE: Patients who are no longer candidates for HDC will be eligible to transfer from Group A to Group B. Group B Phase II: Patients on Group B will receive sal vage chemotherapy consisting of cycles of oral etoposide for 14 days plus oral temozolomide (TMZ) for 5 days monthly until preparation of immunotherapeutic vaccines has been completed as presented below: Patients will undergo a non- mobilized leukapheresis prior to salvage chemotherapy for harvest of peripheral blood mononuclear cells (PBMCs) for TTRNA -xALT and TTRNA -DC generation. Afterwards, mobilized leukapheresis will be attempted after each salvage chemotherapy cycle until enough peripheral blood stem cells (PBSCs) are harvested for autologous stem cell infusion (goal of 2x10 6 CD34+ PBSCs/kg ). Subjects who do not mobilize any peripheral blood stem cells or do not undergo leukapheresis, will continue with immunotherapy witho ut NMA chemotherapy. If either DCs and/ or xALT do not meet release criteria or targeted dose, then the patient may remain on study and receive the qualified product but will be replaced for the purposes of safety assessment. If only DCs are to be administered , then lymphodepleting conditioning with cyclophosphamide/fludarabine will be withheld and DCs administered when the patient has recovered detectable peripheral blood lymphocyte counts as the rationale for lymphodepletion is for enhancing the expansion of adoptively transferred T cells (xALT). Patients who progress prior to immunotherapy may remain on study as long as they continue to meet the other eligibility requirements.